<div id="readability-page-1"><p>Clover Health Investments (NASDAQ:CLOV - Get Free Report) will likely be announcing its  Q1 2026 results after the market closes on Wednesday, May 6th. Analysts expect the company to announce earnings of $0.07 per share and revenue of $714.8940 million for the quarter. Investors may visit the the company's upcoming Q1 2026 earning results page for the latest details on the call scheduled for Wednesday, May 6, 2026 at 5:00 PM ET.</p><ul><li>MarketBeat Week in Review – 03/03 - 03/07</li></ul><p>Clover Health Investments (NASDAQ:CLOV - Get Free Report) last posted its earnings results on Thursday, February 26th. The company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.05). The firm had revenue of $487.71 million for the quarter, compared to analysts' expectations of $467.06 million. Clover Health Investments had a negative return on equity of 25.17% and a negative net margin of 4.45%. On average, analysts expect Clover Health Investments to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year. </p><h2>Clover Health Investments Trading Up 4.8%</h2><p>Clover Health Investments stock opened at $2.64 on Wednesday. The firm has a 50-day moving average of $2.02 and a 200-day moving average of $2.40. The firm has a market cap of $1.39 billion, a P/E ratio of -15.53 and a beta of 2.24. Clover Health Investments has a 1-year low of $1.58 and a 1-year high of $3.92. </p><h2>Wall Street Analyst Weigh In</h2><ul><li>Missed the Hims &amp; Hers Rally? Clover Health Could Be Next</li></ul><p>A number of analysts have recently weighed in on CLOV shares. Leerink Partners dropped their target price on shares of Clover Health Investments from $3.00 to $2.50 and set a &#34;market perform&#34; rating for the company in a report on Thursday, March 5th. Weiss Ratings  reiterated a &#34;sell (d-)&#34; rating on shares of Clover Health Investments in a report on Friday, March 27th. Wall Street Zen upgraded shares of Clover Health Investments from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Sunday, February 15th. Finally, Canaccord Genuity Group dropped their target price on shares of Clover Health Investments from $3.70 to $3.20 and set a &#34;buy&#34; rating for the company in a report on Friday, March 20th. One research analyst  has rated the stock with a Buy rating, three have given a Hold rating and one  has assigned  a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of &#34;Hold&#34; and an average target price of $2.90.</p><p><b>Check Out Our Latest Stock Report on Clover Health Investments</b></p><h2>Insider Buying and Selling at Clover Health Investments</h2><p>In other Clover Health Investments news, CEO Brady Patrick Priest sold 175,000 shares of the firm's stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $2.17, for a total transaction of $379,750.00. Following the completion of the transaction, the chief executive officer owned 1,998,584 shares of the company's stock, valued at approximately $4,336,927.28. This trade represents a 8.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through this link. Corporate insiders own  24.07% of the company's stock. </p><h2>Hedge Funds Weigh In On Clover Health Investments</h2><p>Institutional investors and hedge funds have recently made changes to their positions in the business. Sei Investments Co. bought a new position in shares of  Clover Health Investments during the second quarter valued at approximately $118,000.  Russell Investments Group Ltd. bought a new position in shares of  Clover Health Investments during the third quarter valued at approximately $104,000.  Virtu Financial LLC bought a new position in shares of  Clover Health Investments during the third quarter valued at approximately $101,000.  Canada Pension Plan Investment Board bought a new position in shares of  Clover Health Investments during the second quarter valued at approximately $88,000.  Finally, Mackenzie Financial Corp bought a new position in shares of  Clover Health Investments during the third quarter valued at approximately $80,000. Institutional investors own  19.77% of the company's stock. </p><h2>About Clover Health Investments</h2> (Get Free Report)<p>Clover Health Investments is a technology-driven healthcare company specializing in Medicare Advantage plans for senior populations. The company combines insurance coverage with a proprietary software platform to improve care coordination, outcomes tracking and cost management. By leveraging data analytics, Clover Health aims to deliver personalized care pathways and preventive interventions for its members.  </p><p>At the core of Clover's offering is its Clover Assistant platform, which aggregates clinical and claims data from multiple sources to create real-time insights for physicians and care teams.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Clover Health Investments</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0xPVg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0xPVg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Clover Health Investments Right Now?</h2><p>Before you consider Clover Health Investments, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Clover Health Investments wasn't on the list.</p><p>While Clover Health Investments currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

CLOV

<p>Clover Health Investments (NASDAQ:CLOV) is set to announce its Q1 2026 earnings on May 6, with expectations of $0.07 per share and $714.89 million in revenue. The company previously reported a loss of $0.10 per share for Q4 2025. Analysts have mixed ratings on the stock, with a consensus rating of "Hold" and an average target price of $2.90. CEO Brady Priest recently sold 175,000 shares, reducing his ownership by 8.05%. Institutional investors hold 19.77% of the company's stock, which focuses on Medicare Advantage plans for seniors.</p>

Clover Health Investments (CLOV) Expected to Announce Quarterly Earnings on Wednesday